ALLO
Allogene Therapeutics Inc
1.40$
-2.1%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -99.9% | +11.4% | +4.1% | +19.6% | +41.0% | -43.0% | -4.1% | -36.2% | -26.7% | +0.0% | -300.0% | – | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | +8.7% | +1.6% | -92.5% | -40.1% | +2,397.7% | -92.8% | +1,318.1% | -91.9% | +1,212.5% | -94.8% | +12.3% | +2.1% | -5.8% | -2.7% | +2.2% | +1,316.5% | -11.2% | -92.8% | -4.1% | +1,195.8% | -22.4% | -90.2% | -6.1% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -99.9% | +11.4% | +4.1% | +19.6% | +41.0% | -43.0% | -4.1% | -36.2% | -26.7% | -16,236.4% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -92.8% | +1,026.8% | -91.1% | +70.2% | +26.5% | +35.8% | +25.9% | +23.4% | -14.8% | +12.5% | +8.7% | +1.6% | +5.7% | -5.2% | +12.3% | -8.1% | +11.4% | -5.0% | +11.3% | +18.5% | +6.4% | -22.7% | -25.9% | +18.9% | -4.4% | -3.6% | -11.2% | +0.6% | +11.6% | -20.0% | -22.4% | -8.1% | +1.8% | +5.4% | – | |
| – | +129,750.0% | +382.3% | -9.7% | +28.5% | -10.2% | +8.6% | +5.8% | +1.3% | +2.8% | +1.4% | +4.8% | +3.1% | -4.5% | +14.8% | +1.1% | +5.1% | -0.3% | -2.0% | -3.1% | +11.1% | -10.1% | -1.9% | -8.0% | +1.1% | +0.2% | -6.8% | +1.5% | -5.0% | -3.4% | -4.7% | -3.8% | +0.3% | +2.3% | +47.9% | – | |
| – | +129,750.0% | +5,098.8% | -83.6% | +48.9% | +10.3% | +26.1% | +19.7% | +17.4% | -10.7% | +9.5% | +7.7% | +1.9% | +3.1% | -0.7% | +9.4% | -4.9% | +8.3% | -4.2% | +7.6% | +16.8% | +2.8% | -18.7% | -26.2% | +43.2% | -22.5% | -68.1% | +28.4% | +111.6% | +8.4% | -73.2% | -17.6% | +186.4% | +9.9% | +19.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +100.0% | – | – | – | – | – | -28.2% | -14.3% | -22.3% | -67.2% | +22.1% | -37.0% | -52.7% | -23.7% | +121.8% | +218.1% | +31.4% | -72.2% | – | – | – | -100.0% | – | – | -19.0% | +85.2% | +78.7% | +28.4% | -9.0% | -4.2% | +14.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -569.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.